Patient Characteristics and Treatment Patterns in Patients with Persistent, Recurrent, or Metastatic (P/R/M) Cervical Cancer: A Real-World Data Analysis in the US

OBJECTIVES: Describe real-world patient characteristics and treatment patterns in patients with P/R/M cervical cancer in the US.

METHODS: This study included patients ≥18 years diagnosed with P/R/M cervical cancer from the Tempus real-world database until 2020. Deidentified structured electronic health records data were integrated with unstructured curated data from a network of US oncology practices. A time-based algorithm determined therapy lines. A subgroup analysis of patients diagnosed after 2014 evaluated bevacizumab integration into practice.

RESULTS: 844 women with P/R/M cervical cancer were included. Mean age was 51.9 years, predominant histological type was squamous cell (60.7%), and most patients had metastases at index date (93.5%). 58.6% of patients were White and 16.5% were African American. Most commonly reported comorbidities were diabetes (6.3%), chronic renal disease (3.7%), and chronic obstructive pulmonary disease (2.5%). Of 126 patients with reported HPV test results prior to cancer diagnosis, 71.4% were positive. 68.6% of patients received 1L systemic anticancer treatment within 1.1 months (median) after cancer diagnosis. Most common 1L systemic anticancer regimens were platinum-based cisplatin monotherapy (23.8%) and combination therapy with cisplatin/carboplatin+paclitaxel±bevacizumab (46.8%) of which 25.1% were with bevacizumab. 88.4% of patients receiving 1L cisplatin monotherapy had radiotherapy within 30 days. 39.7% of patients treated with 1L therapy received subsequent 2L systemic treatment. Most frequently prescribed 2L regimens were cisplatin/carboplatin+paclitaxel±bevacizumab (33.9%), pembrolizumab (11.3%), or topotecan (5.2%) monotherapies. Median time-to-treatment discontinuation was 4.0 months both in 1L and 2L. In a subgroup analysis of 511 patients diagnosed after 2014, most common 1L systemic anticancer regimens were platinum-based cisplatin monotherapy (21.3%) and combination therapy with cisplatin/carboplatin+paclitaxel±bevacizumab (52.3%) of which 36% were with bevacizumab.

CONCLUSIONS: Consistent with other real-world data analyses, this analysis suggests that US patients with P/R/M cervical cancer receive 1L care concordant with guidelines. Subgroup analysis showed bevacizumab is integrated into clinical practice.